Navigation Links
Arena Pharmaceuticals Announces First Quarter 2008 Financial Results
Date:5/7/2008

t of payments and fees, if any, from Arena's collaborators, and Arena's ability to redeem with common stock any outstanding shares of its series B convertible preferred stock. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Contacts: Jack Lief Mary Claire Duch

President and CEO WeissComm Partners

Media Relations

David Walsey 212.301.7228

Director, Corporate Communications

Arena Pharmaceuticals, Inc.

858.453.7200, ext. 1682

Arena Pharmaceuticals, Inc.

Condensed Consolidated Statements of Operations

(In thousands, except per share amounts)

Three months ended March 31,

2008 2007

(unaudited)

Revenues

Contract manufacturing $2,019 $ -

Collaborative agreements 590 4,911

Total revenues 2,609 4,911

Operating Expenses

Cost of contract manufacturing 2,330 -

Research and development 47,565 35,755

General and administrative 8,861 4,923

Amortization of acquired technology 3
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Arena Pharmaceuticals to Present at the Bear Stearns 20th Annual Healthcare Conference
2. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
3. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
4. Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index
5. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Arena Pharmaceuticals to Report Third Quarter 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, October 17, 2007
7. Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results
8. Arena Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Arena Pharmaceuticals Appoints Phillip M. Schneider and Randall E. Woods to Board of Directors
10. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
11. Arena Pharmaceuticals Enters Into Strategic Agreements for the Manufacture of Pharmaceutical Material, Including Lorcaserin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... Pearl's Premium Ultra Low Maintenance Lawn Seed ... seed this week with the release of their Pearl's ... the fact that it is time to plant now ... , As of the date 6/4/13, Pearl's Premium had ... experts and the media including: The National Gardeners ...
(Date:9/22/2014)... job it is to stop bleeding, are very simple. ... "feel" the physical environment around them, researchers at Emory ... surfaces with greater stiffness by increasing their stickiness, the ... other components of the clotting system, the researchers found. ... for, in that they are able to sense the ...
(Date:9/22/2014)... to create a highly sensitive chemical sensor based on ... unique electronic properties that the researchers were able to ... 300 times. , The study is available online in ... Amin Salehi- Khojin, asst professor of mechanical and industrial ... and Bijandra Kumar, post doc where they are doing ...
(Date:9/22/2014)... (PRWEB) September 22, 2014 Topical BioMedics, ... those in pain end their suffering, restoring hope an ... model. This is only possible because of the innovative ... healing cream technology a reality. , The company ... NY, by Lou Paradise (president, chief of research, and ...
Breaking Biology Technology:Pearl's Premium Ultra Low Maintenance Lawn Seed Announces A Major Breakthrough In Drought Tolerant Grass Seed 2Platelets modulate clotting behavior by 'feeling' their surroundings 2Graphene imperfections key to creating hypersensitive 'electronic nose' 2Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 2Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 3Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 4Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 5Topical BioMedics (Topricin) Celebrates 20 Years of Providing Hope and Quality of Life...As Topricin Is Declared “The 21st Century Standard of Care for Pain Management” 6
... West Central Wisconsin Workforce Resource is inviting representatives ... Synergy Conference titled "Positioning for Economic Growth." , ,The conference ... a.m. to 5 p.m. and Sept. 21 from 8 a.m. ... Memorial Student Center . , ,Although some speakers have ...
... - Mithridion, Inc. , a biopharmaceutical startup that is ... secured $296,800 in federal grants to evaluate tests for drug ... Institute on Aging , a branch of the U.S. ... the feasibility of the tests. If successful, the company will ...
... Wis. - The recent decision by a young researcher ... some of the financial consequences of the same-sex union debate ... and nanotechnology researcher, has won $3.4 million in grants since ... year, he will take his knowledge and research with him ...
Cached Biology Technology:Conference to address small town development 2Mithridion wins grants for Alzheimer's research 2Mithridion wins grants for Alzheimer's research 3Departure of nanotech researcher stings UW 2Departure of nanotech researcher stings UW 3
(Date:9/21/2014)... to what was previously thought, newborn immune T cells ... to bacteria, according to a new study led by ... differently to that of adults, babies may still be ... study published in the journal Nature Medicine . ... different types of immune cells, including neutrophils which play ...
(Date:9/19/2014)... today by researchers from several Harvard University labs ... experienced and aspiring researchers with the intellectual raw ... made from soft, flexible materials. , With the ... other advances in manufacturing technology, soft robotics is ... drawn from conventional rigid robot design, but working ...
(Date:9/19/2014)... Imagine you are a species which over thousands of years ... exposed to a substance that makes the cold dangerous for ... Enchytraeus albidus , and the cold provoking substance, called ... cosmetics. , Nonylphenol is suspected of being a endocrine disruptor, ... It inhibits the worm,s ability to protect the cells in ...
Breaking Biology News(10 mins):Immune system of newborn babies is stronger than previously thought 2Soft robotics 'toolkit' features everything a robot-maker needs 2Environmental pollutants make worms susceptible to cold 2Environmental pollutants make worms susceptible to cold 3
... were not the only ones with visions of sugar plums ... a new research report published in the January 2010 issue ... ), a team of scientists from the University of Texas ... compound from licorice root (glycyrrhizin from Glycyrrhiza glabra ) ...
... DALLAS Jan. 4, 2010 An experimental drug currently ... fighting the brain cancer glioblastoma and prostate cancer, researchers at ... The drug,s actions, observed in isolated human cells in ... encouraging because they attacked not only the bulk of the ...
... origin of the Devil Facial Tumour Disease (DFTD) that has ... scientists has discovered. Devil Facial Tumour Disease (DFTD) ... was first reported in 1996. It is spread by biting ... large tumours, mostly on the face and mouth, which often ...
Cached Biology News:A trip to the candy store might help ward off rare, but deadly infections 2Experimental drug shows promise against brain, prostate cancers 2Nervous culprit found for Tassie devil facial tumor disease 2
Rabbit polyclonal to Shigella (HRP) ( Abpromise for all tested applications)....
... PhosphoPlus™ SAPK/JNK (Thr183/Tyr185) Antibody Kit ... (Thr183/Tyr185) Antibody, Catalog #9251, 200 ul ... 200 ul SAPK/JNK Cell Extracts, Catalog ... HRP-linked Antibody, Catalog #7074, 100 ul ...
Anti-gp120/160(SIV/mac239) Immunogen: gp120(SIV/mac239) protein (Genebank accession #M33262)...
Annexin V Binding Buffer, 10X Concentrate Buffer , 50 ml Consult technical datasheet for details....
Biology Products: